J&J Under CEO Gorsky Will Remain Diverse But Be More Selective
This article was originally published in The Pink Sheet Daily
New CEO Alex Gorsky outlines his vision for the healthcare giant in his first quarterly sales and earnings presentation to investors. Short-term priorities include restoring OTC drug supply and building pharmaceutical sales momentum.
You may also be interested in...
Emerging markets were a mixed picture for Big Pharma in the third quarter, with China the clear leader, but overall key markets continued to see slower growth, which many blamed on the slowdown in the West.
In addition to patent expiries, which affected pharma company performance globally, ongoing price cuts for drugs and increasing parallel trade continued to hurt pharma’s European performance in the second quarter, with the gloom unlikely to lift soon. What’s at stake is further pharma investment in Europe.
The agency’s decision not to approve the Factor Xa inhibitor for treating acute coronary syndrome patients follows a negative recommendation by an FDA advisory committee, which was concerned about missing data in the pivotal ATLAS trial. FDA may be seeking more clarity on the issue of missing vital status follow-up for patients who withdrew consent in that study.